Paper Details

  1. Home
  2. Paper Details

Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.

Author: , JuliussonGunnar, SamuelssonHenrik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cladribine, a prodrug used to treat hairy cell leukemia, has a long-term survival rate of >80% in patients under 60 years of age, but <50% in older patients.
Paper Details　
Original Abstract of the Article :
Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients dia...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/10428194.2011.565842

データ提供：米国国立医学図書館（NLM）

Hairy Cell Leukemia: Epidemiology, Pharmacokinetics of Cladribine, and Long-Term Follow-Up

Hairy cell leukemia (HCL) is a rare type of blood cancer, like a hidden oasis in a vast desert, often challenging to diagnose and treat. This research explores the epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous cladribine therapy for HCL. The study highlights the male predominance of HCL, with a 4:1 ratio, and analyzes survival rates based on age and treatment modality. The study also examines the pharmacokinetic properties of cladribine, including its bioavailability and long-term efficacy.

Cladribine Therapy for Hairy Cell Leukemia: Long-Term Efficacy and Improved Quality of Life

This study provides important insights into the epidemiology, pharmacokinetics, and long-term outcomes of cladribine therapy for HCL. The findings demonstrate the effectiveness of cladribine, particularly in younger patients, and highlight the potential for long-term survival and improved quality of life. This research contributes to our understanding of this rare cancer and its treatment.

Living with HCL: Seeking Early Diagnosis and Treatment

HCL is a treatable cancer. Early diagnosis and appropriate treatment are essential for improving outcomes. If you experience any symptoms of HCL, it's important to consult with a healthcare provider for a thorough evaluation. Don't hesitate to seek medical attention if you have concerns about your health.

Dr. Camel's Conclusion

This research provides a comprehensive overview of hairy cell leukemia, exploring its epidemiology, the pharmacokinetics of cladribine, and the long-term outcomes of subcutaneous cladribine therapy. The study highlights the effectiveness of cladribine as a treatment option for HCL, especially in younger patients. The findings offer hope for patients with this rare cancer, demonstrating the potential for long-term survival and improved quality of life.
Date :
  1. Date Completed 2011-09-29
  2. Date Revised 2019-01-16
Further Info :

Pubmed ID

21599605

DOI: Digital Object Identifier

10.3109/10428194.2011.565842

Related Literature

Article Analysis
・Effects of cladribine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.